End-of-day quote
Korea S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
1,650
KRW
|
+1.10%
|
|
+1.23%
|
+3.51%
|
04-24 |
EQ Maxon Pharmaceutical Co., Ltd., LAT Co.,Ltd. and Yeju Industrial Co. Ltd. cancelled the acquisition of 30.9% stake in Zinitix Co., Ltd. from Seoul Electronics & Telecom Co., Ltd, Wonwoo Kim and Sua Kim
|
CI
| 04-12 |
LAT Co.,Ltd. and Yeju Industrial Co. Ltd. cancelled the acquisition of 30.9% stake in Zinitix Co., Ltd. from Seoul Electronics & Telecom Co., Ltd, Wonwoo Kim and Sua Kim.
|
CI
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
95,522
|
88,798
|
115,101
|
47,899
|
56,979
|
Enterprise Value (EV)
1 |
81,934
|
74,293
|
99,322
|
41,381
|
53,581
|
P/E ratio
|
191
x
|
-343
x
|
-1,087
x
|
-5.28
x
|
-9.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,738,504
x
|
2,198,348
x
|
2,963,999
x
|
1,734,778
x
|
1,723,051
x
|
EV / Revenue
|
1,738,504
x
|
2,198,348
x
|
2,963,999
x
|
1,734,778
x
|
1,723,051
x
|
EV / EBITDA
|
15,000,464
x
|
33,752,785
x
|
43,707,505
x
|
-10,674,943
x
|
-10,837,694
x
|
EV / FCF
|
-
|
-141,692,383
x
|
-194,307,958
x
|
-7,020,692
x
|
-46,070,590
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
3.34
x
|
2.94
x
|
3.83
x
|
2.19
x
|
3.52
x
|
Nbr of stocks (in thousands)
|
33,873
|
35,591
|
35,746
|
35,746
|
35,746
|
Reference price
2 |
2,820
|
2,495
|
3,220
|
1,340
|
1,594
|
Announcement Date
|
2/29/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
54,945
|
40,393
|
38,833
|
27,611
|
33,068
|
EBITDA
|
-
|
6,368
|
2,631
|
2,633
|
-4,487
|
-5,257
|
EBIT
1 |
-44.66
|
5,430
|
1,555
|
1,607
|
-5,229
|
-6,047
|
Operating Margin
|
-
|
9.88%
|
3.85%
|
4.14%
|
-18.94%
|
-18.29%
|
Earnings before Tax (EBT)
1 |
-8.901
|
629.5
|
-350.5
|
-118.8
|
-6,966
|
-5,878
|
Net income
1 |
-6.943
|
446.2
|
-256.9
|
-105.6
|
-9,065
|
-5,878
|
Net margin
|
-
|
0.81%
|
-0.64%
|
-0.27%
|
-32.83%
|
-17.77%
|
EPS
2 |
-2.344
|
14.80
|
-7.276
|
-2.962
|
-253.7
|
-164.5
|
Free Cash Flow
|
-
|
-
|
-626.7
|
-592.4
|
-6,823
|
-1,237
|
FCF margin
|
-
|
-
|
-1.55%
|
-1.53%
|
-24.71%
|
-3.74%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/19
|
2/29/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
13,588
|
14,506
|
15,779
|
6,518
|
3,397
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-627
|
-592
|
-6,823
|
-1,237
|
ROE (net income / shareholders' equity)
|
-0.07%
|
2.45%
|
-0.87%
|
-0.35%
|
-34.9%
|
-30.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
2.3%
|
2.36%
|
-8.8%
|
-12.7%
|
Assets
1 |
-
|
-
|
-11,161
|
-4,471
|
103,053
|
46,246
|
Book Value Per Share
2 |
1,888
|
845.0
|
849.0
|
842.0
|
612.0
|
453.0
|
Cash Flow per Share
|
-
|
247.0
|
365.0
|
150.0
|
29.40
|
138.0
|
Capex
|
-
|
413
|
55
|
230
|
388
|
118
|
Capex / Sales
|
-
|
0.75%
|
0.14%
|
0.59%
|
1.4%
|
0.36%
|
Announcement Date
|
3/1/19
|
2/29/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
|
1st Jan change
|
Capi.
|
---|
| +3.51% | 42.66M | | +10.19% | 16.46B | | +26.45% | 16.34B | | +8.68% | 9.39B | | -20.73% | 7.82B | | +3.53% | 6.44B | | +68.43% | 5.25B | | -4.63% | 4.69B | | +68.24% | 4.51B | | +0.89% | 4.43B |
Other Corporate Financial Services
|